Business Context and Reporting Period
This Form 8-K is a current report filed by NeuroBo Pharmaceuticals, Inc. (not Metavia Inc. as indicated in metadata) on September 29, 2022, regarding events occurring on September 27, 2022. The company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol NRBO.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on regulatory compliance status.
Material Changes
The primary material event is the resolution of a listing deficiency. On September 27, 2022, the Company received formal notification from The Nasdaq Stock Market LLC confirming it has regained compliance with Nasdaq Listing Rule 5550(a)(2). This rule requires issuers to maintain a closing bid price of at least $1.00 per share. Consequently, the listing matter is now closed, and the Company satisfies all other applicable criteria for continued listing.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the resolution of the prior listing deficiency. A press release dated September 29, 2022, is incorporated by reference as Exhibit 99.1.
Investor Verification Checklist
- Verify the current trading price of NRBO to ensure continued compliance with the $1.00 minimum bid price requirement.
- Review the press release filed as Exhibit 99.1 for additional context on the compliance restoration.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Note the discrepancy between the metadata company name (Metavia Inc.) and the actual registrant (NeuroBo Pharmaceuticals, Inc.).